

7th of May 2019

First day of trading in FluoGuide's shares and warrants at Spotlight Stock Market

Today is the first day of trading in FluoGuide A/S's ("FluoGuide") shares and warrants of series TO 1. FluoGuide's shares are traded under the ticker "FLUO" with ISIN DK0061123312 and FluoGuide's warrants of series TO 1 are traded under the ticker "FLUO TO1" with ISIN DK0061138773.

Ahead of the listing at Spotlight Stock Market, FluoGuide has conducted a successful IPO which has provided the company approx. DKK 15.9 million before issue costs and approx. 1,500 new shareholders. The issue funds will primarily finance advancing the first product FG001 towards the market and broad clinical use. The total number of shares in FluoGuide is 7,224,274 shares and the share capital amounts to DKK 722,427.40. In addition, there are a total of 1,074,758 warrants of series TO 1. Each warrant of series TO 1 entitles the holder the right to subscribe for one (1) new share in FluoGuide at a subscription price of DKK 5.95 per share during the exercise period April 16th – May 7th, 2020.

Financial advisor, legal advisor and Selling Agent

Sedermera Fondkommission is acting as financial advisor and issuing agency to FluoGuide in connection with the listing at Spotlight Stock Market. Markets & Corporate Law is legal advisor.

For further information about the listing, please contact:

Sedermera Fondkommission
Telephone: +46 (0) 40-615 14 10
E-mail: info@sedermera.se
Website: www.sedermera.se

For further information about FluoGuide, please contact:

Morten Albrechtsen, CEO, FluoGuide A/S
Telephone: +45 24 25 62 66
E-mail: ma@fluoguide.com
Website: www.fluoguide.com

About FluoGuide

FluoGuide A/S develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue. Preclinical studies have demonstrated the potential of FG001 to vastly improve the radical surgery (removal of all cancer) and thereby improving outcome and likelihood of survival. FluoGuide is initially focused on glioblastoma (brain tumor) but the Company plan to expand its business to other solid tumors. Market launch of FG001 in a first country is expected in 2022/2023.